Pharmaceutical

Merck KGaA nears $3.5bn deal for SpringWorks

Merck KGaA has confirmed that it is in late-stage discussions with SpringWorks, valuing the deal at a price of around $47 per share.

Apr 26, 2025 - 06:00
Merck KGaA nears $3.5bn deal for SpringWorks
Merck KGaA has confirmed that it is in late-stage discussions with SpringWorks, valuing the deal at a price of around $47 per share.
Read the original article

Tags:

Previous Article

City of Hope Researchers Showcase Cutting-Edge Discoveries at AACR Annual Meeting

Next Article

FDA free to pursue semaglutide compounders after latest court ruling

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Orion gets grant for cyp11a1 inhibitors for treating pr...

Aug 23, 2024

STAT+: Delfi launches its blood test to screen for lung cancer – and reveals challenges for liquid biopsies

STAT+: Delfi launches its blood test to screen for lung...

Oct 10, 2023

Y-mAbs’ Danyelza injection receives marketing approval in Brazil

Y-mAbs’ Danyelza injection receives marketing approval ...

May 24, 2023